Study provides clarity on use of anticoagulants in gastrointestinal cancers
Those bereaved during pandemic inform national end of life care survey
4 June 2021Researchers yield new insights into origins of synovial sarcoma
4 June 2021Study provides clarity on use of anticoagulants in gastrointestinal cancers
A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers. The findings were published Wednesday, June 2, in Mayo Clinic Proceedings.
